Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [¹⁷⁷Lu]Lu-DOTA-MGS5 in Patients with Small Cell Lung Cancer.

ABSTRACT: Background/Objectives: Peptide receptor radionuclide therapy (PRRT) is an established treatment for neuroendocrine tumors (NETs), enabling targeted radiation delivery via radiolabeled peptides. Small cell lung cancer (SCLC) remains a major therapeutic challenge due to its aggressive nature and poor prognosis. Despite advances, relapse rates are high and effective therapies are limited. We previously demonstrated the diagnostic potential of the cholecystokinin-2 receptor (CCK2R)-targeting minigastrin analog [⁶⁸Ga]Ga-DOTA-MGS5 in PET/CT imaging of different NETs. Building on this, we developed and evaluated [¹⁷⁷Lu]Lu-DOTA-MGS5 as a therapeutic PRRT agent. Methods: Preclinical studies investigating the receptor-mediated cellular internalization and intracel

SUBMITTER: Zavvar TS 

PROVIDER: S-EPMC12844804 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature